

**Cystic
Fibrosis Trust**



Clinical Trials Accelerator Platform

Impact Report 2025

Uniting for a life unlimited

Cystic Fibrosis Trust established the Clinical Trials Accelerator Platform (CTAP) in 2017 to increase access to clinical research for people with cystic fibrosis (CF).



The platform also supports clinical trial sponsors in delivering a wide range of studies across the UK, helping to enhance the country's capacity for CF research.

Since its launch, we have supported **74 CF studies**, enabled thousands of people to participate, and reduced the time it takes to deliver a study at CF centres around the UK.

This report highlights CTAP's achievements over the last 12 months (June 2024–May 2025) and showcases the broader impact we've made since the platform was launched.

CTAP is a hugely beneficial collaboration that is clearly increasing clinical trial opportunities for people with CF across the UK, and speeding up the development of new and better treatments for people with CF."

Dr Tim Lee, Leeds Regional Paediatric Cystic Fibrosis Centre

The Trust Facebook post on YOGA-CF* was really useful. I used the details to get in touch with the trial organisers."


Person with CF, who used Trust resources to inform her participation in a clinical study

(*Study on yoga and quality of life in adults with CF)


Our network of clinical trial centres

CTAP supports a nationwide network of 25 CF centres, funding the majority with a CF trial coordinator, and creating a comprehensive trial infrastructure in the UK.


Six of our centres are also early-phase research centres, equipped with the infrastructure needed to support clinical trials in their early stages. With CTAP centres reaching approximately **90% of people with CF in the UK**, we're significantly expanding access to research opportunities. Our dedicated trial coordinators play a vital role in accelerating trial set-up and delivery at their centres. Beyond operational support, CTAP provides a platform for collaboration, training, education, and quality improvement, making it easier than ever for centres to deliver high-quality clinical research for the UK CF community.



Our impact since CTAP began



Our impact this year



Impactful CTAP projects

Within the CTAP network, we have several initiatives to help us reach more people with CF, ensuring that everyone has the opportunity to take part in clinical research.

Regional clinical trial networks

We established networks in London, Scotland and North England, and the South West to support the CF community within these regions to have easier access to studies. We're planning to develop a network in the North West next.

Referring people with CF for trial participation

To widen access to trials for more of the CF population, we link CTAP trial coordinators with CF centres around the UK to inform as many CF centres and their respective patients about relevant clinical trial opportunities. Our CTAP trial coordinators support CF centres with referring patients to take part in many different types of research, from studies trialling new genetic therapies to ones focused on monitoring CF complications in children.

Diversity in clinical trials

We launched a project to identify and address the barriers that affect people with CF from underrepresented groups, including those from minority ethnic groups, and other underserved members of the CF community from participating in clinical research.

Community involvement and engagement

More than 350 community members are registered to our Involvement Group, all bringing their unique and diverse experience to activities such as focus groups and trial documentation reviews to ensure we are making clinical research studies as accessible as possible to our community.

In the last year, 19 people with CF have been referred to a CTAP centre to take part in a clinical research study

- 16 studies involving children
- 1 genetic therapy trial
- 6 CFTR modulator trials


During 2024,

100+

involvement and engagement activities were facilitated

CTAP study portfolio

To date, **74 studies** have been supported by CTAP, with more studies coming through into the pipeline. In line with our **research goals** to develop effective treatments for all and to be able to treat all the symptoms of CF throughout the body, we have grown a portfolio which includes a wide range of therapeutic areas and diverse age groups and demographics.



As CF research has evolved, so has our portfolio of CTAP supported studies, including the first genetic therapy studies to be trialled in CF. These important studies aim to look at treatments for those with rare genotypes, including those that do not respond or do not tolerate current CFTR modulator therapies.


Find out more about these studies on the [Trials Tracker](#).

Looking ahead

In collaboration with the European Cystic Fibrosis Society's Clinical Trials Network (ECFS-CTN), CTAP has successfully achieved its goal of establishing the UK as a world leading country for the delivery of CF clinical research studies.

The past year has been very successful for CTAP, with continued engagement in clinical studies from the CF community. The growing interest from pharmaceutical companies wishing to open studies in the UK has resulted in a large and diverse portfolio of CF clinical research.

CTAP's impact has transformed the landscape of CF research in the UK by supporting a widespread network of CF centres. Looking ahead, CTAP aims to further establish the UK as a highly desirable location for early phase CF clinical trials, including those focused on genetic therapies, ensuring the UK CF community, both professionals and people with CF, are at the forefront of supporting innovative and transformative treatments.



Early phase genetic therapy studies are available at 11 of the 25 CTAP centres.